Fedratinib Induces Spleen Responses and Reduces Symptom Burden in Patients with Myeloproliferative Neoplasm (MPN)-Associated Myelofibrosis (MF) and Low Platelet Counts, who were Either Ruxolitinib- -Naïve or were Previously Treated with Ruxolitinib
Claire N Harrison1, Nicolaas Schaap2, Alessandro M Vannucchi3, et al.
1 Department of Clinical Haematology, Guy's and St Thomas NHS Foundation Trust, London,United Kingdom
2 Radboud University Medical Centre, Nijmegen, Netherlands
3 AOU Careggi, University of Florence, Florence, Italy
Program: Oral and Poster Abstracts Type: Oral Session: 634. Myeloproliferative Syndromes: Clinical: JAK Inhibitors and Combination Therapies Hematology Disease Topics & Pathways: Diseases, Adult, Therapies, MPN, Study Population, Clinically Relevant, Myeloid Malignancies Monday, December 9, 2019: 11:45 AM W311EFGH, Level 3 (Orange County Convention Center) Authors Claire N Harrison1, Nicolaas Schaap2,...